Join us at the 5th PREDiCT: Tumor Models Immuno-Oncology Summit

Join us at the 5th PREDiCT: Tumor Models Immuno-Oncology Summit

Hello All,

I hope you are staying safe and well.

Despite the challenging year, we have seen huge progress and commitment to advance preclinical immune-oncology research. We are committed to helping you and the wider community, and are excited to be partnering with 5th PREDiCT: Tumor Models Immuno-Oncology Summit (formerly San Francisco, Jan 26 – 28 2021) to bring you the latest insights and data in the comfort of your home.

Kimberly Aardalen, Scientific Technical Leader, Novartis Institute for Biomedical Research and I will be hosting a Breakfast Workshop, focusing on Software Solutions for the Animal Study Reproducibility Crisis and Enhanced Animal Welfare, take a look at the full agenda here.

We have secured ten 20% discounted passes for our customers, register here and quote SPN20 for your exclusive pass.

Through practical examples and discussions, Kimberly and I will give you takeaways on:

  • What animal study workflow software applications can help you standardize study design, conduct and analysis
  • How the software does your usual heavy lifting, effortlessly facilitating protocol and procedural oversight, animal welfare compliance, and real-time results analysis, reporting and graphing, task scheduling
  • Preserving data securely for stakeholder access especially in this remote working environment

I hope to see you (virtually) in January at this exciting workshop, alongside other senior IO experts from AstraZeneca, Fate Therapeutics, Novartis, Bicycle Therapeutics and many more., and reserve your front row seat now.

Finally, if you had a few minutes to spare, I gave an interview to the PREDiCT: Tumor Models team, to shed new highlights on preclinical IO researchers, and why powerful software is critical to future studies – you can read it here.

Very best,


Eric Ibsen
President & CEO
Workshop Partner, 5th PREDiCT: Tumor Models for Immuno-Oncology

No Comments

Sorry, the comment form is closed at this time.